Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 18/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.65 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | NPY1R | P25929 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583267 | 0.99 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Hydrochloric Acid SCHEMBL3776559 | 0.99 | ESR1 (0.98) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL4325515 | 0.99 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Hydrochloric Acid SCHEMBL3776804 | 0.93 | ESR1 (0.87) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Hydrochloric Acid SCHEMBL3769936 | 0.92 | ESR1 (0.87) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL20234943 | 0.92 | ESR1 (0.84) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL282599 | 0.90 | ESR1 (0.82) | ESR1ESR2 | |
| SCHEMBL14032457 | 0.90 | ESR1 (0.83) | ESR1ESR2 | |
| SCHEMBL22297087 | 0.89 | ESR1 (0.80) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL20211899 | 0.89 | ESR1 (0.80) | ESR1ESR2MLNRNR1I2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| EP-0883404-B1 | COMBINATION THERAPY FOR OSTEOPOROSIS | PFIZER (US) | 2008-08-20 | — | — | EP | claimed |
| EP-1932543-A2 | Combination therapy for osteoporosis consisting of an estrogen agonist/antagonist and a growth hormone secretagogue | Pfizer, Inc. (US) | 2008-06-18 | — | — | EP | claimed |
| EP-1106179-B1 | Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions | PFIZER (US) | 2008-05-28 | — | — | EP | claimed |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | SPROUT PHARMACEUTICALS, INC. | 2008-05-01 | — | — | US | claimed |
| EP-0989993-B1 | TARTRATE SALT OF A SUBSTITUTED DIPEPTIDE AS GROWTH HORMONE SECRETAGOGUE | PFIZER PROD INC (US) | 2008-03-05 | — | — | EP | claimed |
| US-7255984-B2 | Combination therapy for osteoporosis | PFIZER INC. (US) | 2007-08-14 | — | — | US | claimed |
| EP-1383482-B1 | METHOD FOR MANUFACTURING A LOW DOSE PHARMACEUTICAL COMPOSITION | PFIZER PROD INC (US) | 2007-07-18 | — | — | EP | claimed |
| EP-0869968-A1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1998-10-14 | — | — | EP | claimed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | claimed |
| EP-0842661-A2 | Atherosclerosis treatment | PFIZER INC. (US) | 1998-05-20 | — | — | EP | claimed |
| EP-0802910-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER INC. (US) | 1997-10-29 | — | — | EP | claimed |
| WO-1997031640-A1 | COMBINATION THERAPY FOR OSTEOPOROSIS | PFIZER INC. (US) | 1997-09-04 | — | — | WO | claimed |
| EP-0792642-A1 | Method of treating conditions with estrogen agonists | PFIZER INC. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0792641-A1 | Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions | PFIZER INC. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0792645-A1 | Combination therapy to treat osteoporosis | PFIZER INC. (US) | 1997-09-03 | — | — | EP | claimed |
| WO-1997024369-A1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1997-07-10 | — | — | WO | claimed |
| WO-1996021656-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER, INC. (US) | 1996-07-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | ESR1 303/4885ESR2 616/4885MLNR 2439/4885 |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | ESR1 303/4885ESR2 616/4885MLNR 2439/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | ESR1 303/4885ESR2 616/4885MLNR 2439/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | ESR1 303/4885ESR2 616/4885MLNR 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.